21 CFR 814.112
§ 814.112 Filing an HDE.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 814.112, § 814.112 Filing an HDE, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/88882
- Permanent ID
ys:prov:88882@1- SHA-256
1c4c989643cc392ef68385fa6c2a5132ccce87f51b3431d8d3ca4db7594804b5
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) The filing of an HDE means that FDA has made a threshold determination that the application is sufficiently complete to permit substantive review. Within 30 days from the date an HDE is received by FDA, the agency will notify the applicant whether the application has been filed. FDA may refuse to file an HDE if any of the following applies:
(1) The application is incomplete because it does not on its face contain all the information required under § 814.104(b);
(2) FDA determines that there is a comparable device available (other than another HUD approved under this subpart or a device under an approved IDE) to treat or diagnose the disease or condition for which approval of the HUD is being sought; or
(3) The application contains an untrue statement of material fact or omits material information.
(4) The HDE is not accompanied by a statement of either certification or disclosure, or both, as required by part 54 of this chapter.
(b) The provisions contained in § 814.42(b), (c), and (d) regarding notification of filing decisions, filing dates, the start of the 75-day review period, and applicant's options in response to FDA refuse to file decisions shall apply to HDE's.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.